Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Feb 3;53(5 Suppl):S28-34.
doi: 10.1016/j.jacc.2008.10.037.

Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum

Rhonda M Cooper-DeHoff  1 , Michael A Pacanowski, Carl J Pepine
Affiliations
Review

Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum

Rhonda M Cooper-DeHoff et al. J Am Coll Cardiol. .

Abstract

Certain cardiovascular drugs have adverse effects on glucose homeostasis, which may lead to important long-term implications for increased risks of adverse outcomes. Thiazide diuretics, niacin, and beta-adrenergic blockers impair glucose homeostasis. However, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated beneficial metabolic effects. The newer vasodilating beta-blocking agents and calcium antagonists appear to be metabolically neutral. These considerations, in addition to meticulous attention to blood pressure control and lifestyle changes, have the potential to beneficially modify glycemia and long-term risks. These considerations have particular importance in younger patients who may also have pre-diabetes or the metabolic syndrome and who are likely to require therapy over the course of decades.

PubMed Disclaimer

Conflict of interest statement

Disclosure statements: Dr. Cooper-DeHoff, Dr. Pacanowski, and Dr. Pepine all have no conflict of interest to report.

Figures

Figure 1
Figure 1. Cardiovascular Disease: Coincidence of Hypertension, CAD, and Diabetes
Inner circles and outer circles represent diagnosed and undiagnosed hypertension, CAD, and diabetes, respectively. Areas and their overlaps are roughly proportional to estimated prevalence of these conditions in the US population. Larger outer area represents incidence of metabolic syndrome, which includes prehypertension, prediabetes, and dyslipidemia. (2,10) CAD = coronary artery disease
Figure 2
Figure 2. Risk of Diabetes by Base- and Added-Strategy Drug Dose in Hypertensive CAD Patients
Reference (hazard ratio 1.0) = atenolol 50 mg/day monotherapy. Data from the International Verapamil SR-Trandolapril Study (INVEST). CAD = coronary artery disease; HCTZ = hydrochlorothiazide
Figure 3
Figure 3. Relationship between Follow-up Systolic BP and Development of Diabetes
Unadjusted relative hazard is shown (triangles) for follow-up systolic BP (mean of measurements before diabetes development or censoring) with reference (hazard ratio 1.0) of 130 mm Hg, the cut-off for metabolic syndrome. With multivariable adjustment this relationship persists (6). Data from the International Verapamil SR-Trandolapril Study (INVEST). BP = blood pressure
See this image and copyright information in PMC

References

    1. American Diabetes Association [online] [Accessed August 21, 2008]. Available at: http://www.diabetes.org/advocacy-and-legalresources/cost-of-diabetes.jsp.
    1. American Heart Association. Heart Disease and Stroke Statistics 2008 Update [online] [Accessed August 21, 2008]. Available at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.187998.
    1. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004;44:637–42. - PubMed
    1. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care. 2005;28:1588–93. - PubMed
    1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–90. - PubMed

Publication types

MeSH terms